Abstract:

Counterfeiting medicines is a global phenomenon affecting developed and less developed countries. The World Health Organization, in its report, describes counterfeit medicines as becoming “a global public health crisis. This study examines consumers, stakeholders, and policymakers' perceptions of NAFDAC anti-counterfeit technologies and interventions regarding counterfeit drugs in Nigeria. This study uses a qualitative research method to examine consumers, stakeholders, and policymakers' perceptions of NAFDAC anti-counterfeit technologies and interventions regarding counterfeit drugs in Nigeria. Participants were selected using convenience sampling, and data was collected through an online interview. Data were analysed using thematic analysis. Stakeholders emphasised the importance of NAFDAC having a comprehensive anti-counterfeiting strategy and implementing measures such as checking for NAFDAC registration numbers, inspecting packaging, and requesting seller receipts to identify genuine medicines. Policymakers at NAFDAC acknowledge the seriousness of the problem and recognise the roles of stakeholders in implementing anti-counterfeiting interventions. They emphasise the need for effective communication, engagement, and collaboration with healthcare professionals. Consumers express concerns about the accessibility to good quality medicines and the prevalence of substandard and counterfeit drugs. However, consumers also demonstrate a willingness to support NAFDAC's efforts and show a preference for quality medicines, which is a positive indicator for the Nigerian pharmaceutical industry. The findings underscore the importance of continuous efforts to raise awareness and implement effective anti-counterfeiting strategies to safeguard public health and combat the growing threat of fake drugs.

References:

[1] Feldschreiber, Peter. 2009. “Public Health Issues with Counterfeit Medicines.” Clinical Medicine, Journal of the Royal College of Physicians of London 9 (1): 63–64. https://doi.org/10.7861/clinmedicine.9-1-63.

[2] WHO. 2017. “A Study on Public Health and Socio-Economic Impact of Substandard and Falsified Medical Products.” World Health Organization 2017, 1–67. https://www.who.int/publications/i/item/9789241513432.

[3] WHO. 2010. “Counterfeit Medical Products – Provisional Agenda Item.

[4] WHO. 2012. “Medicines: Spurious/Falsely-Labelled/Falsified/Counterfeit (SFFC) Medicines,.” http://www.who.int/mediacentre/factsheets/fs275/en/.

[5] Almuzaini, Tariq, Imti Choonara, and Helen Sammons. 2013. “Substandard and Counterfeit Medicines: A Systematic Review of the Literature.” BMJ Open 3 (8): 1–7. https://doi.org/10.1136/bmjopen-2013-002923.

[6] Ubajaka, Chika F, Alphonsus C Obi-okaro, Obiageli F Emelumadu, Maureen N Azumarah, Andrew U Ukegbu, and Samuel O Ilikannu. 2016. “Factors Associated with Drug Counterfeit in Nigeria : A Twelve Year Review” 12 (4): 1–8. https://doi.org/10.9734/BJMMR/2016/21342.

[7] Akunyili, D. 2010. “The Challenges Faced by NAFDAC in the National Regulatory Process as It Relates to Essential Drugs for Prevention of Maternal and Newborn Deaths in Nigeria.” Tropical Journal of Obstetrics and Gynaecology 27 (April 2010). http://www.sogon.org/Journal 2010/SOGON 2010 Publication 4 int-net Jrnal Vol 27 No1/The Challengees faced...By Dora Akunyili.pdf.

[8] Amadi, Luke, and Michael Amadi2. 2014. “Sustainable Drug Consumption, Regulatory Dynamics and Fake Drug Repositioning in Nigeria: A Case of NAFDAC.” Journal of Scientific Issues 2 (9): 412–19. http://www.sci-afric.org.

[9] NAFDAC. 2010. “The National Agency for Food and Drug Administration and Control (NAFDAC) Mobile Authentication Service Scheme Guidelines for the Procurement and Management of the NAFDAC Mobile Authentication Service (MAS) Scheme.” NAFDAC’s MAS Implementation Guide.

[10] NAFDAC. 2017. “NAFDAC Anti-Counterfeiting Strategies.” 2017. https://www.nafdac.gov.ng/about-nafdac/nafdac-anti-counterfeiting-strategies/.

[11] Njogu, GG, and L Gichinga. 2016. “Factors Influencing Procurement Performance in State Corporations in Kenya.” International Journal of Innovative Research and Development 5 (6): 196–215. http://www.ijird.com/index.php/ijird/article/view/94309.

[12] Britannica. 2023. “Lagos Nigeria.” 2023. https://www.britannica.com/place/Lagos-state-Nigeria.

[13] Igwenagu, Emmanuel. 2021. “Kano Population.” https://nigerianinformer.com/kano-state-population/.

[14] Nigeria Galleria. 2021. “Brief History of Kano State.” 2021. https://www.nigeriagalleria.com/Nigeria/States_Nigeria/Kano/Brief-History-of-Kano.html.

[15] World Polulation Review. 2021. “Abuja Population 2021.” 2021. https://worldpopulationreview.com/world-cities/abuja-population.

[16] Bansal, Dipika, Swathi Malla, Kapil Gudala, and Pramil Tiwari. 2013. “Anti-Counterfeit Technologies: A Pharmaceutical Industry Perspective.” Scientia Pharmaceutica 81 (1): 1–13. https://doi.org/10.3797/scipharm.1202-03.

[17] NAFDAC. 2013. “Curbing the Influx of Substandard Regulated Products.” NAFDAC.

[18] Okereke, Melody, Ignatius Anukwu, Sola Solarin, and Mazi Sam Ohuabunwa. 2021. “Combatting Substandard and Counterfeit Medicines in the Nigerian Drug Market: How Industrial Pharmacists Can Rise Up to the Challenge.” INNOVATIONS in Pharmacy 12 (3): 15. https://doi.org/10.24926/iip.v12i3.4233.

[19] Liu, Rui, and Susanne Lundin. 2016. “Falsified Medicines : Literature Review Falsified Medicines : Literature Review,” no. January.

[20] WHO. 2023. “Guidelines: Norms and Standards for Pharmaceuticals.” https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines.

[21] Ojonugwa, Agbo Friday, Dr Gwom, and Solomon Gwom. 2021. “The Role and Challenges of the National Agency for Food and Drug Administration and Regulation of Alternative Medicine in Nigeria,” no. August: 0–2. https://www.wahooas.org/web-ooas/sites/default/files/publications/2186/harmonised-framework-tmpok_0.pdf.

[22] Adisa, Rasaq, Omotola Rukayat Adeniyi, and Titilayo Oyelola Fakeye. 2019. “Knowledge, Awareness, Perception and Reporting of Experienced Adverse Drug Reactions among Outpatients in Nigeria.” International Journal of Clinical Pharmacy 41 (4): 1062–73. https://doi.org/10.1007/s11096-019-00849-9.

[23] Onuh, Gideon, Simon Karanja Hinga, Boniface Makori Nyamweya, and Atayero A. Aderemi. 2022. “Assessment of Consumers ’ Awareness and Ability to Identify Counterfeit Drugs in Developing Countries in Africa – a Cross Sectional Study Based on Online Survey,” 1–15. https://www.researchsquare.com/article/rs-998393/v2.